MedTrace Logo

Treatment Trial of Alveolar Echinococcosis

NCT07182305 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2025-09-19

No results posted yet for this study

Summary

A new focus of subjects with lesions of alveolar echinococcosis caused by Echinococcus multilocularis has been found south of Gulcha in Osh province in Kyrgyzstan by an ultrasound surveillance. Prevalence of infections is approximately 6%. Most lesions are small. Current scientific evidence suggests that in the absence of treatment, alveolar echinococcosis has a case fatality rate approaching 100% within 10-15 years of infection. Albendazole is known to be effective as a parasitostatic treatment to prolong the life of subjects with this disease, possibly up to normal life expectancy with prolonged treatment. The trial will be a case control study to evaluate the treatment of subjects with early stage alveolar echinococcosis and the progression of disease.

Conditions

  • Alveolar Echinococcosis

Interventions

DRUG

Efficacy of albendazole for early stage intervention of alveolar echinococcosis

Participants in the treatment arm will be treated with albendazole, 2 x 400 mg daily for the duration of the study. Treatment may be prolonged beyond the end of the study if clinically appropriate.

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Ministry of Health, Kyrgyzstan

    lead OTHER_GOV

Principal Investigators

  • Gulnara Minbaeva, MD · Department of disease prevention and sanitary - epidemiological surveillance, Ministry of Health of the Kyrgyz Republic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2021-04-30
Completion
2023-07-31

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07182305 on ClinicalTrials.gov